pharmaceutical biotechnology

Acquisition brings Avidity’s RNA delivery platform and late-stage neuromuscular programs under Novartis, expanding its capabilities in developing precision genetic medicines.

The collaboration combines Celonic’s biologics expertise with Carbogen Amcis’s payload and conjugation capabilities to create a seamless, end-to-end ADC development pathway.

The drugmaker expands access to AI-driven discovery, but also positions its technology to become a standard across the sector.

Experts discussed the major hurdles of AAV gene therapy, including immunogenicity, vector design, and AAV variability.

Boost your pharmaceutical career with an online master’s in pharmaceutical sciences. Learn drug development and precision medicine through eLearning.